EPL Ltd Q1 Revenue Jumps 25%; Company Raises Growth Guidance

INDUSTRIAL-GOODSSERVICES
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
EPL Ltd Q1 Revenue Jumps 25%; Company Raises Growth Guidance

EPL Limited reported a 25.3% surge in revenue for Q1 FY27, backed by consistent double-digit growth. Despite a slight dip in reported profit due to tax phasing, the company hiked its revenue growth guidance to high teens, signaling strong operational momentum across all key global regions.

EPL Ltd Reports 25.3% Revenue Growth, Hikes Guidance

Revenue grew 25.3% in Q1 FY27, while EBITDA rose 15.2% during the quarter.

Reader Takeaway: Strong global revenue growth drives upward guidance, though investors must track European margin recovery and rising net debt.

What just happened

EPL Limited announced robust performance for the first quarter of FY27. Revenue reached double-digit growth for the fifth consecutive quarter. Underlying revenue growth stood at 20%, excluding pass-through impacts. While reported PAT fell 1.4% due to tax phasing, PBT climbed 10%. Management clarified that the effective tax rate for the full year is expected to normalize between 20% and 22%.

Why this matters

The company’s decision to increase its revenue growth guidance from early double digits to high teens reflects high confidence in global demand. Broad-based growth was led by the EAP region at 34.3%, followed by Americas at 29.4%, Europe at 20.2%, and AMESA at 17%.

Operational Strategy

EPL is investing in capacity and front-end specialization to capture market share. In the Americas, margin volatility is being addressed through sales team restructuring. In Europe, the company is tackling specific operational challenges with a target of returning to mid-teen margins in upcoming quarters. Meanwhile, the Indovida merger has received CCI approval and continues to progress as planned.

Risks to watch

Investors should monitor the rising net debt, which management attributes to higher inventory costs and strategic safety stock build-ups. The timeline for margin recovery in Europe remains a primary operational focus. Synergy realization from the Indovida merger will be a key performance indicator in the coming months.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.